Acumen Pharma up on FDA's 'fast track' tag for Alzheimer's therapy

Acumen Pharmaceuticals

24/10/2022 19:13

** Shares of Acumen Pharmaceuticals Inc  ABOS.O  rise ~2% to
$7.8
    ** U.S. FDA grants "fast track" designation to Acumen's
experimental therapy, ACU193, in early stage trial for treatment
of early Alzheimer's disease  urn:newsml:reuters.com:*:nGNX4xbjJz
    ** Alzheimer's disease is a neurodegenerative disease that
causes the brain to shrink and brain cells to die 
    ** A fast track designation facilitates development and
expedites review of therapies with the potential to treat a
serious condition where there is an unmet medical need 
    ** All 6 brokerages covering the stock rate it "buy" or
higher; their median PT is $16.50 - Refinitiv data
    ** Including session moves, stock up 15.24% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))